Speciality
Spotlight

   




 


Dermatology & Venereology


 

     






AIDS

Human Immunodeficiency Virus Infection

    

  • Breton G, Fillet A-M, Katlama C, et al [ Hopital Pitie Salpetriere, Paris]


    Acyclovir-Resistant Herpes Zoster in Human Immunodeficiency Virus Infected Patients: Results of Foscarnet Therapy



    Clin Infect Dis 27: 1525-1527, 1998


      


    Eighteen patients of isolation confirmed varicella-zoster virus [ VZV] infection manifesting as herpes zoster in HIV-1 positive subjects are reported. They were resistant to acyclovir-therapy. Thirteen subjects received IV foscarnet in a dose of 100 mgm/kg twice a day. In one patient the dose had to be reduced to 120 mgm because of hypocalcemia lesion clearance was achieved in ten patients five relapsed with recurrence in the same dermatomes in a little over three months after treatment. Three of these cleared with acyclovir or foscarnet. Of the total of 16 followed for a median of 8 months 4 died of visceral effects of VZV infections. Normally the drug is used in a dose of 40 mgm/Kg thrice a day or 60 mgm/kg twice a day. It is important to note that patients tolerated the larger dose. Message of the paper is “acyclovir resistant herpes zoster is a serious in patients of Aids.”

       

  • EI Hachem M, Bernardi S, Pianosi G, et al [ Bambino Gesu Children’s Hosp and Health Research Inst, Rome


    Mucocutaneous Manifestations in Children With HIV Infection and AIDS



    Pediatr Dermatol 15: 429-434, 1998


       


    In a 5 year period with a follow-up of 31 months [average], 166 HIV positive children in an average age group of 14.8 months, were taken for study. Of these, 81 children became HIV negative spontaneously indicating lack of infection. Of the remaining 85 HIV-positive children, 76 revealed a minimum of 1 skin effect. These comprised infestations, infections, and inflammatory diseases. They increased as the immune depletion progressed. Despite tumour rarity in children Kaposi sarcoma was diagnosed in one child.

        


    This article highlights the importance of seroreversal in infants, rare occurrence of tumours in childhood HIV infection and reports a single possible Kaposi sarcoma. Candidosis topped all other infections.

        

  • Cattelan
    AM, Calabro ML, Aversa SML, et
    al [Gen Hosp of Padova, Italy;
    Univ of Padova, Italy]


    Regression
    of AIDS-Related Kaposi’s
    Sarcoma Following
    Antiretroviral Therapy with
    Protease Inhibitors:
    Biological Correlates of
    Clinical Outcome


    Eur
    J Cancer 35: 1809-1815, 1999

      

    Eleven
    HIV-1 positive males [Median
    age, 43 years] with worsening
    Kaposi’s Sarcoma [KS] proved
    histologically 
    were treated with 2
    nucleoside reverse
    transcriptase inhibitors [NRTI]
    and a protease inhibitor
    constituting the highly active
    antiretroviral therapy [HAART].
    The treatment was for 16
    months [median]. HIV-1 RNA
    levels, CD4+ counts, HHV-8
    antibody levels were repeated
    every month.

     

    Complete
    reversal of KS including
    visceral lesion and edema
    occurred in 6 patients. 3
    showed a partial response,
    documented by flattening of KS
    lesions or a 50% reduction of
    tumors without development of
    new lesions for 4 weeks.
    In these 9 patients,
    the CD4+ rose, HIV-1 RNA and
    HHV-8 [especially ORF65 or
    lytic related] levels became
    lower.

      

    In
    the remaining 2 patients all
    parameters became worse.

        


 



 

    

Speciality Spotlight

   

     

AIDS
Human Immunodeficiency Virus Infection
    

  • Breton G, Fillet A-M, Katlama C, et al [ Hopital Pitie Salpetriere, Paris]
    Acyclovir-Resistant Herpes Zoster in Human Immunodeficiency Virus Infected Patients: Results of Foscarnet Therapy
    Clin Infect Dis 27: 1525-1527, 1998
      
    Eighteen patients of isolation confirmed varicella-zoster virus [ VZV] infection manifesting as herpes zoster in HIV-1 positive subjects are reported. They were resistant to acyclovir-therapy. Thirteen subjects received IV foscarnet in a dose of 100 mgm/kg twice a day. In one patient the dose had to be reduced to 120 mgm because of hypocalcemia lesion clearance was achieved in ten patients five relapsed with recurrence in the same dermatomes in a little over three months after treatment. Three of these cleared with acyclovir or foscarnet. Of the total of 16 followed for a median of 8 months 4 died of visceral effects of VZV infections. Normally the drug is used in a dose of 40 mgm/Kg thrice a day or 60 mgm/kg twice a day. It is important to note that patients tolerated the larger dose. Message of the paper is “acyclovir resistant herpes zoster is a serious in patients of Aids.”
       

  • EI Hachem M, Bernardi S, Pianosi G, et al [ Bambino Gesu Children’s Hosp and Health Research Inst, Rome
    Mucocutaneous Manifestations in Children With HIV Infection and AIDS
    Pediatr Dermatol 15: 429-434, 1998
       
    In a 5 year period with a follow-up of 31 months [average], 166 HIV positive children in an average age group of 14.8 months, were taken for study. Of these, 81 children became HIV negative spontaneously indicating lack of infection. Of the remaining 85 HIV-positive children, 76 revealed a minimum of 1 skin effect. These comprised infestations, infections, and inflammatory diseases. They increased as the immune depletion progressed. Despite tumour rarity in children Kaposi sarcoma was diagnosed in one child.
        
    This article highlights the importance of seroreversal in infants, rare occurrence of tumours in childhood HIV infection and reports a single possible Kaposi sarcoma. Candidosis topped all other infections.
        

  • Cattelan AM, Calabro ML, Aversa SML, et al [Gen Hosp of Padova, Italy; Univ of Padova, Italy]
    Regression of AIDS-Related Kaposi’s Sarcoma Following Antiretroviral Therapy with Protease Inhibitors: Biological Correlates of Clinical Outcome
    Eur J Cancer 35: 1809-1815, 1999
      
    Eleven HIV-1 positive males [Median age, 43 years] with worsening Kaposi’s Sarcoma [KS] proved histologically  were treated with 2 nucleoside reverse transcriptase inhibitors [NRTI] and a protease inhibitor constituting the highly active antiretroviral therapy [HAART]. The treatment was for 16 months [median]. HIV-1 RNA levels, CD4+ counts, HHV-8 antibody levels were repeated every month.
     
    Complete reversal of KS including visceral lesion and edema occurred in 6 patients. 3 showed a partial response, documented by flattening of KS lesions or a 50% reduction of tumors without development of new lesions for 4 weeks. In these 9 patients, the CD4+ rose, HIV-1 RNA and HHV-8 [especially ORF65 or lytic related] levels became lower.
      
    In the remaining 2 patients all parameters became worse.
        

 

 

By |2022-07-20T16:44:20+00:00July 20, 2022|Uncategorized|Comments Off on AIDS

About the Author: